Major shareholder announcement
June 21, 2024 05:53 ET
|
Novozymes A/S
June 21, 2024 Company announcement No. 22 Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that Novo Nordisk Fonden has on its own behalf and on behalf of its...
The era of biosolutions. Outlook upgraded for 2024
June 17, 2024 13:09 ET
|
Novozymes A/S
Novonesis is performing very well and the 2024 outlook for pro forma organic sales growth is now expected at the upper end of the 5-7% range while the pro forma adjusted EBITDA margin is increased to...
Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees
June 06, 2024 05:28 ET
|
Novozymes A/S
June 6, 2024Company announcement No. 20 Incentive program for the Executive Leadership Team 2024-2026 In line with previous year, a new long-term incentive program (LTI) for the...
Trading by management and close relations of management
May 31, 2024 05:26 ET
|
Novozymes A/S
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...
Trading by management and close relations of management
May 29, 2024 10:59 ET
|
Novozymes A/S
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...
Trading by management and close relations of management
May 17, 2024 06:39 ET
|
Novozymes A/S
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...
Trading by management and close relations of management
May 08, 2024 09:21 ET
|
Novozymes A/S
Please read the full announcement in PDF
Attachment
2024_16_Trading_By_Management
...
Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration
May 03, 2024 01:57 ET
|
Novozymes A/S
For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA...
Trading statement Q1 2024
May 03, 2024 01:56 ET
|
Novozymes A/S
Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO: “I am pleased with the first quarter organic sales growth of 4%...
Resolutions from the annual shareholders’ meeting 2024
April 30, 2024 12:02 ET
|
Novozymes A/S
Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:• Approval of the audited Annual Report for 2023• Approval of distribution of profit with payment of an...